Physician profile
Ginger Debose
NPI 1265136246
$863.32
in general payments reported to CMS, 2019-2025
17 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Gerontology (Nurse Practitioner) provider received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $4.87 · 2024: $607 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $839 · Education: $23.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $839.34 |
| Education | $23.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $117.95 | 2024-2025 | Velphoro, Velphoro |
| Akebia Therapeutics INC | $104.46 | 2024 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $95.03 | 2024-2025 | |
| Travere Therapeutics, INC. | $91.15 | 2023-2025 | |
| Ardelyx, INC. | $79.03 | 2024-2025 | Ibsrela |
| Astrazeneca Pharmaceuticals LP | $74.11 | 2024-2025 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.74 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $50.99 | 2024 | |
| Novo Nordisk INC | $34.21 | 2024-2025 | Ozempic, Rybelsus |
| Amgen INC. | $26.66 | 2024 | Tavneos |
| Otsuka America Pharmaceutical, INC. | $21.73 | 2024 | Jynarque |
| Opko Pharmaceuticals, LLC | $20.90 | 2024 | Rayaldee |
| Lilly USA, LLC | $20.20 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $19.89 | 2024 | Acthar |
| Calliditas Therapeutics US INC. | $19.43 | 2025 | Tarpeyo |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $18.20 | 2024 | Veltassa |
| Aurinia Pharma U.S., INC. | $17.64 | 2025 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ginger Debose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.